/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Xenetic Biosciences Inc Share Price Today: Live Updates & Key Insights

Xenetic Biosciences Inc share price today is $2.57, up -2.47%. The stock opened at $2.51 against the previous close of $2.63, with an intraday high of $2.51 and low of $2.51.

Xenetic Biosciences Inc Share Price Chart

style
pb-0

Xenetic Biosciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Xenetic Biosciences Inc Share Price Performance

$2.57 -0.0247(-2.47%) XBIO at 13 Mar 2026 03:56 PM Biotechnology
Lowest Today 2.51
Highest Today 2.51
Today’s Open 2.51
Prev. Close 2.63
52 Week High 13.93
52 Week Low 1.90
Day’s Range: Low 2.51 High 2.51
52-Week Range: Low 1.90 High 13.93
1 day return -
1 Week return +0.59
1 month return +17.2
3 month return +9.65
6 month return -24.07
1 year return -5.37
3 year return -28.43
5 year return -90.53
10 year return -

Xenetic Biosciences Inc Institutional Holdings

Renaissance Technologies Corp 7.79

Sachetta LLC 0.67

Geode Capital Management, LLC 0.47

Fidelity Extended Market Index 0.40

Vanguard Institutional Extnd Mkt Idx Tr 0.29

JTC Employer Solutions Trustee Ltd 0.12

Fidelity Nasdaq Composite Index 0.09

Fidelity Series Total Market Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.04

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

UBS Group AG 0.02

State St US Extended Mkt Indx NL Cl C 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

SSgA U.S. Total Market Index Strategy 0.01

Fidelity U.S. Equity Index Ins Trust 0.00

Bank of America Corp 0.00

Morgan Stanley - Brokerage Accounts 0.00

Harwood Advisory Group, LLC 0.00

LGT Group Foundation 0.00

SBI Securities Co Ltd 0.00

Xenetic Biosciences Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Xenetic Biosciences Inc Fundamentals

Market Cap 6.03 M

PB Ratio 1.5295

PE Ratio 0.0

Enterprise Value 1.93 M

Total Assets 6.90 M

Volume 28569

Xenetic Biosciences Inc Company Financials

Annual Revenue FY23:2354995 2.4M, FY22:1706925 1.7M, FY21:1160692 1.2M, FY20:436942 0.4M, FY19:17066 0.0M

Annual Profit FY23:null 0.0M, FY22:1706925 1.7M, FY21:1160692 1.2M, FY20:436942 0.4M, FY19:17066 0.0M

Annual Net worth FY23:-4445607 -4.4M, FY22:-6386798 -6.4M, FY21:-5544712 -5.5M, FY20:-10893466 -10.9M, FY19:-15949915 -15.9M

Quarterly Revenue Q3/2025:1026956 1.0M, Q2/2025:589897 0.6M, Q1/2025:593261 0.6M, Q3/2024:614243 0.6M, Q2/2024:726404 0.7M

Quarterly Profit Q3/2025:1026956 1.0M, Q2/2025:589897 0.6M, Q1/2025:593261 0.6M, Q3/2024:614243 0.6M, Q2/2024:726404 0.7M

Quarterly Net worth Q3/2025:-509939 -0.5M, Q2/2025:-688703 -0.7M, Q1/2025:-903141 -0.9M, Q3/2024:-436671 -0.4M, Q2/2024:-1273970 -1.3M

About Xenetic Biosciences Inc & investment objective

Company Information Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. James F. Parslow

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow